Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 28, 2025Advanced ScienceOpen Access

Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKailun FeiJZJie ZhaoJXJiachen Xu

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved progression-free survival in advanced non-small cell lung cancer, indicating ctDNA-guided treatment may optimize outcomes.

Key Points

  • Progression-free survival improved significantly with tumor-informed ctDNA-guided treatment in advanced non-small cell lung cancer.
  • Patients with ctDNA positivity receiving immunochemotherapy had a hazard ratio of 0.45 for progression-free survival and 0.66 for overall survival.
  • Randomized phase III trial compared immunochemotherapy to chemotherapy in advanced non-small cell lung cancer, validating ctDNA metrics.
  • Highlights the independent predictive value of tumor-informed ctDNA over other immune biomarkers in selecting effective treatments.

Cite This Study

Fei et al. (2025) studied this question.

synapsesocial.com/papers/6928f12ea65b730b9ea7a896https://doi.org/10.1002/advs.202506565
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers2025
  2. 2Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy2024 · 18 citations
  3. 3Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis2026
  4. 4Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer2026 · 1 citations
  5. 5Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.2024 · 5 citations